Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 743 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Ibrutinib-Containing Immunochemotherapy in Front-Line Treatment of Young, Medically Fit Patients with... May 14, 2024 Registered Dietitian vs. Nutritionist March 3, 2021 Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer May 8, 2020 Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers November 15, 2023 Load more HOT NEWS Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... Insights Into the Biology of Response and Resistance to MAPK Pathway... ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March How will new cancer medicines be approved in the future?
